The advisory committee on immunization practices recommended PREVNAR 20 for adults aged 50 and above

Pfizer recently announces that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practice voted to expand its recommendation for the use of certain pneumococcal vaccines, including PREVNAR 20 for all adults aged 50 and older. This recommendation is pending final approval by the director of the CDC and the Department of Health and Human Services. With respect to PREVNAR 20, ACIP recommended:

• Vaccination is recommended for all adults aged ≥50 years and for adults aged 19–49 years with certain underlying conditions or risk factors who have not received a PCV or whose vaccination history is unknown.

“ACIP’s vote to expand adult pneumococcal vaccination to now include all adults aged 50 and older marks an important milestone in Pfizer’s long-standing commitment to reducing the burden of this life-threatening disease,” said Luis Jodar, PhD, Senior Vice President, Vaccines and Anti-Infectives Chief Medical Affairs Officers, Pfizer. “PREVNAR 20 offers protection against the serotypes responsible for the majority of invasive pneumococcal disease cases in this age group. Expanding its use also provides an opportunity to limit the re-emergence of disease-causing strains like serotype 4, which has recently affected certain U.S. adult populations and is covered by the vaccine.”

---

---

Related Topics and Keywords

Pfizer, PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine)